You are here: Industry Insights > Wuxi Biologics

News List

I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs Wuxi Biologics
September 27, 2018
WuXi Biologics and I-Mab Biopharma jointly announce today that I-Mab has expanded strategic collaboration with WuXi Biologics and licensed proprietary WuXiBody™ Platform to develop three bispecific antibodies.
WuXi Biologics Appoints Harvard Professor David R. Liu to Scientific Advisory Board en-cphi.cn
September 25, 2018
WuXi Biologics announced the appointment of David R. Liu, Richard Merkin Professor and Vice-Chair of the Faculty at the Broad Institute, and Howard Hughes Medical Institute (HHMI) Investigator, as a member of its Scientific Advisory Board (SAB).
WuXi Biologics’ Chief Quality Officer Received Foreign Post Service Award from FDA en-cphi.cn
September 18, 2018
WuXi Biologics today announced that Dr. Chiang Syin, Chief Quality Officer of WuXi Biologics, was honored with the “Foreign Post Service Award” for his contributions in the FDA China Office.
WuXi Biologics and Inhibrx Enter an Exclusive Partnership for GMP Manufacturing en-cphi.cn
September 11, 2018
The agreement showcases the expansive biologics pipeline of Inhibrx and the world leading technical expertise and capabilities of WuXi Biologics.
WuXi Biologics Selected into the Hang Seng HK 35 Index en-cphi.cn
August 30, 2018
WuXi Biologics (2269.HK) announced that the company has been selected by Hang Seng Indexes as a constituent of the Hang Seng HK 35 Index (“HSHK35”) effective 10 September, 2018.
WuXi Biologics Reports Robust 2018 Interim Results en-cphi.cn
August 21, 2018
WuXi Biologics announced its unaudited interim results for the six months ended June 30, 2018 today.
WuXi Biologics Announced Successful Completion of the First cGMP Run in MFG3 Wuxi Biologics
July 31, 2018
One of the largest biologics clinical manufacturing facilities globally with 6 production lines which enable WuXi Biologics to complete 60 IND-enabling projects per year
WuXi Biologics to invest $60 million for its first overseas site in U.S. biospectrumasia
June 11, 2018
WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.
WuXi Biologics to build new facility in Singapore biospectrumasia
May 28, 2018
The new manufacturing facility will be the company’s first overseas site in Asia and second site outside of China
WuXi Biologics, Bioasis in Strategic Dev./Mfg. Alliance contractpharma
May 22, 2018
WuXi Biologics and Bioasis Technologies, Inc. have entered an initial strategic collaboration for the development and manufacture of xB3-001, Bioasis' lead biologic candidate to treat brain cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page